Thus, the tumor cell autonomous IFN program induction by TKIs and other oncogene-targeted drugs may variably signal in a paracrine fashion as well as through autocrine mechanisms to mediate heterogeneity of individual patient responses within an oncogene-defined set of lung cancer patients. The gene discussed is IFNA1; the disease is neoplasm.